We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $268M
1-Year Est. Return 158.98%
This Fund
S&P 500
This Quarter Est. Return
+39.3%
1 Year Est. Return
+158.98%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$223M
AUM Growth
+$77.2M
Cap. Flow
+$48M
Cap. Flow %
21.55%
Top 10 Hldgs %
25.3%
Holding
464
New
223
Increased
67
Reduced
60
Closed
103

Sector Composition

1 Healthcare 52.36%
2 Technology 13.57%
3 Financials 11.27%
4 Communication Services 4.48%
5 Energy 3.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ASND icon
151
Ascendis Pharma A/S
ASND
$17.1B
$391K 0.18%
1,832
-4,498
-71% -$929K
HRMY icon
152
Harmony Biosciences
HRMY
$1.96B
$390K 0.18%
10,434
-1,066
-9% -$35K
SLB icon
153
SLB Ltd
SLB
$70.3B
$384K 0.17%
+10,000
New +$363K
VIR icon
154
Vir Biotechnology
VIR
$1.59B
$383K 0.17%
+63,550
New +$378K
MPLT
155
MapLight Therapeutics
MPLT
$1.72B
$382K 0.17%
+21,766
New +$365K
COR icon
156
Cencora
COR
$59.9B
$378K 0.17%
+1,119
New +$381K
AMLX icon
157
Amylyx Pharmaceuticals
AMLX
$1.97B
$376K 0.17%
31,147
+8,234
+36% +$112K
KTTA icon
158
Pasithea Therapeutics
KTTA
$15M
$375K 0.17%
+290,555
New +$255K
AVBH
159
Avidbank Holdings
AVBH
$353M
$373K 0.17%
14,033
-16,097
-53% -$418K
AMZN icon
160
Amazon
AMZN
$2.66T
$369K 0.17%
+1,600
New +$366K
MRK icon
161
Merck
MRK
$315B
$365K 0.16%
+3,471
New +$326K
LQDA icon
162
Liquidia Corp
LQDA
$7.11B
$363K 0.16%
+10,536
New +$300K
SNY icon
163
Sanofi
SNY
$107B
$361K 0.16%
+7,445
New +$369K
ZYME icon
164
CALL
Zymeworks
ZYME
$1.78B
$359K 0.16%
649
+198
+44% +$4.32K
XERS icon
165
Xeris Biopharma Holdings
XERS
$1.52B
$358K 0.16%
45,609
+28,407
+165% +$224K
ARDX icon
166
Ardelyx
ARDX
$1.28B
$353K 0.16%
60,490
-31,556
-34% -$176K
GLUE icon
167
Monte Rosa Therapeutics
GLUE
$2.07B
$348K 0.16%
+22,211
New +$299K
SLNO
168
DELISTED
Soleno Therapeutics
SLNO
$343K 0.15%
7,416
-33,843
-82% -$1.86M
RIGL icon
169
Rigel Pharmaceuticals
RIGL
$750M
$342K 0.15%
+7,995
New +$301K
NTRA icon
170
Natera
NTRA
$38.9B
$340K 0.15%
+1,484
New +$310K
WVE icon
171
Wave Life Sciences
WVE
$1.12B
$337K 0.15%
+19,827
New +$201K
PCRX icon
172
Pacira BioSciences
PCRX
$1.01B
$335K 0.15%
12,962
-613
-5% -$14.6K
INCY icon
173
PUT
Incyte
INCY
$23.4B
$329K 0.15%
+266
New +$25.7K
JAZZ icon
174
CALL
Jazz Pharmaceuticals
JAZZ
$15.5B
$329K 0.15%
283
+54
+24% +$8.28K
GOSS icon
175
CALL
Gossamer Bio
GOSS
$83.2M
$328K 0.15%
2,401
+472
+24% +$1.35K

Similar funds

Persistent Asset Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Persistent Asset Partners held 464 positions worth $223M, up 53% from $145M the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Persistent Asset Partners deployed $48M of net new capital in Q4 2025, opening 223 new positions and adding to 67 existing holdings. Its largest new stake was Molina Healthcare: 51,285 shares worth $8.9M.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 49% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was UnitedHealth, an estimated $3.15M trimmed.

  • Persistent Asset Partners's largest Q4 2025 buy was Molina Healthcare: 51,285 shares worth $8.9M.
  • Persistent Asset Partners added most to Elevance Health in Q4 2025, an estimated $5.15M increase.
  • Persistent Asset Partners's biggest Q4 2025 reduction was UnitedHealth, cutting an estimated $3.15M.
  • Persistent Asset Partners fully exited iShares 7-10 Year Treasury Bond ETF in Q4 2025, selling an estimated $4.82M.
  • Persistent Asset Partners's ten largest holdings make up 25% of its $223M portfolio in Q4 2025.
  • Persistent Asset Partners opened 223 new positions and closed 103 in Q4 2025.
  • Persistent Asset Partners's portfolio value rose 53% quarter-over-quarter to $223M.

Based on Persistent Asset Partners's 13F filing for Q4 2025, filed 17 Feb 2026.